Stahl's Essential Psychopharmacology Online
In Collaboration With
Index
The 
-icon indicates content; the 
-icon indicates figures; the 
-icon indicates tables.
- EAAT. See excitatory amino acid transporters (EAAT)
- eating disorders, , ,
- and reward circuits,
- SSRIs for,
- “ecstacy”,
- SERT transport of,
- ECT (electroconvulsive therapy),
- ectopic sites, hypersensitivity to stimuli,
- Effexor XR. See venlafaxine XR (Effexor XR; Efexor XR)
- efficacy, path to,
- efficacy profile,
- EGF (epidermal growth factor),
- eicosapentanoic acid (EPA), as mood stabilizer,
- Elavil (amitriptyline, Endep, Tryptizol, Loroxyl), , ,
- elderly
- antidepressants for, ,
- circadian rhythms of, ,
- depression,
- citalopram for,
- treatment,
- risperidone for,
- electrical integrator, axon hillock as, ,
- electrical signals
- axon for propagating, ,
- and chemical signals, in neurotransmission,
- conversion to chemical message,
- electroconvulsive therapy (ECT),
- elevated mood circuits,
- EMD128130 (sarizotan),
- emotion
- amygdala response to input,
- brain component regulating, ,
- CSTC loop to regulate, ,
- depressed patient neuronal response,
- mesocortical prefrontal cortex and,
- mesolimbic dopamine pathway role in,
- processing,
- brain areas impacting,
- emotional abuse, and synaptogenesis,
- emotional learning, amygdala and,
- emotional maturity, constant synaptic revision and,
- emotional/motivation pathway,
- emotional symptoms, of dementia,
- emotional trauma, circuit response to,
- en passant presynaptic axon terminals,
- enantiomers, for citalopram,
- Endep (amitriptyline, Elavil, Tryptizol, Loroxyl), , , . See also nortriptyline (Pamelor, Endep, Aventyl)
- endocannabinoids (ECs), ,
- endocrine reactions, to fear,
- endogenous growth factors
- and neurogenesis in hippocampus, ,
- promoting production, ,
- “endogenous marijuana”,
- endogenous opiate neurotransmitters,
- endogenous opioid peptides, and descending inhibition
- endokinins,
- endophenotypes, ,
- endorphins, , ,
- energy
- loss
- bupropion for,
- as SSRI side effect,
- for neurotransmission,
- enhancer element, of gene regulatory region,
- enkephalins, ,
- enteric nervous system,
- enthusiasm, loss
- bupropion for,
- as SSRI side effect,
- environment,
- factors in ADHD,
- environmental stress,
- genetic abnormalities and, ,
- enzymes
- activation in signal transduction cascade,
- binding to G protein,
- fast transport of,
- function of,
- inhibitors of,
- as possible indirect target by psychotropic drugs,
- as psychopharmacological drug action site, ,
- substrate binding to,
- targeted by psychotropic drugs,
- EPA (eicosapentanoic acid), as mood stabilizer,
- ephaptic cross-talk, ,
- ephedrine,
- with MAOIs, and hypertension,
- epidermal growth factor (EGF), ,
- epilepsy, from improper neuronal migration,
- epileptic neurons,
- eplivanserin (SR 46349),
- EPS. See extrapyramidal symptoms (EPS)
- Epworth Sleepiness Scale, ,
- ERB signaling system, neuregulin activation of,
- erectile dysfunction, ,
- age and,
- pharmacology,
- prevalence of,
- depression and, ,
- treatment,
- erectile function,
- ERK (extracellular signal-regulated kinase),
- ERT (estrogen replacement therapy), , ,
- erythromycin, and CYP 450 3A4,
- escitalopram, ,
- icon,
- eslicarbazepine, ,
- actions as mood stabilizer,
- essential amino acids,
- Essential Psychopharmacology: The Prescriber’s Guide (Stahl), ,
- estazolam
- half-life of,
- for insomnia,
- estradiol
- activity-dependent spine formation by,
- receptors for,
- estrogen, ,
- for Alzheimer’s disease,
- as GABA inhibitor,
- as glutamate activator,
- impact on cytoplasmic receptors,
- interaction with monoamines
- and depressed mood,
- vasomotor symptoms from,
- and nuclear hormone receptors, ,
- regulation and major depression, over female life cycle,
- and sexual motivation,
- and trophic actions, on dendritic spine formation,
- tropic properties,
- estrogen receptors,
- estrogen replacement therapy (ERT), , ,
- estrogen response elements, ,
- eszopiclone, ,
- and R zopiclone,
- euphoria, from opiates,
- euthymia, on mood chart, ,
- evidence-based selection of antidepressants, algorithm, ,
- excitation-secretion coupling, , , , ,
- excitatory amino acid transporters (EAAT), , ,
- for glutamate takeup,
- excitatory neurotransmission,
- “excitotoxic hypothesis of schizophrenia”,
- excitotoxicity, , , , ,
- in ALS
- cellular events during,
- in early fetal brain development,
- and glutamate systems, ,
- and neuronal insult,
- executive dysfunction, ,
- in ADHD,
- biological endophenotype for,
- localization in dorsolateral prefrontal cortex,
- symptoms of,
- executive functioning, ,
- in ADHD patients,
- genetic influence on circuits regulating,
- impaired
- in dementia,
- in schizophrenia,
- prefrontal cortex synaptogenesis and,
- regulation
- by CSTC loop,
- by mesocortical dopamine pathway,
- tests of,
- exercise
- and endogenous growth factors,
- and neurogenesis in hippocampus, ,
- “exercising” the brain,
- extracellular portion of receptor,
- extrapyramidal symptoms (EPS), ,
- 5HT2A antagonist to reduce, ,
- absence with atypical antipsychotics,
- D2 receptor blockage and,
- dopamine partial agonism and,
- risperidone and,
- SDAs and
- from unwanted D2 receptor blockade,
- extroversion, in hyperthymic temperament,
- exuberance, in hyperthymic temperament,